West Pharmaceutical Services (NYSE:WST – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and ...
West Pharmaceutical Services Inc. closed 47.37% below its 52-week high of $400.88, which the company reached on March 21st.
New Mexico Educational Retirement Board decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) ...
We recently published a list of These Were Last Week’s 10 Worst Performers. In this article, we are going to take a look at ...
West Pharmaceutical’s earnings results led to a 38% drop. Find out why WST stock could be worth watching for future rebounds ...
Shares of West Pharmaceutical Services Inc. rose 7.84% to $214.73 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.01% to ...
West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its stock performance has been volatile, with annual returns of 66% in 2021, ...
West Pharmaceutical Services (WST) stock was upgraded to Buy at Deutsche Bank due to an attractive entry point post-selloff. Read more here.
Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results